NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m. ET in New York, NY. Oppenheimer 36th Annual Healthcare Life Sciences Conference. Fireside chat ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Lexeo Therapeutics, Inc. is placed sixteenth on our list. TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating. The firm believes that the market is still not persuaded by LXEO’s recent PKP2 findings; the drop implies a lesser possibility of acceptance for the PKP2 program. H.C. Wainwright Says Market Remains Unconvinced on Lex ...

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company’s continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny Venture Fund ...

Company Overview - Lexeo Therapeutics is focused on delivering therapies for patients with challenging diseases, particularly in reshaping heart health [3] - The company's first program targets Friedreich's ataxia, with plans to address other similar diseases in the future [3] Technology and Innovation - Lexeo Therapeutics utilizes a differentiated delivery system with the AAVrh10 capsid, which is a highly cardiotropic vector suitable for heart disease treatment [4] - The company has developed an innovative manufacturing platform capable of supplying both small and large indications for cardiac diseases [4] Financial Position - Lexeo Therapeutics maintains a strong financial position and possesses significant operating experience in the field of cardiac genetic medicine [4]

Lexeo Therapeutics Conference Call Summary Company Overview - **Company**: Lexeo Therapeutics (NasdaqGM:LXEO) - **Industry**: Biotechnology, specifically focusing on cardiac genetic medicines and therapies for Friedreich's ataxia and arrhythmogenic cardiomyopathy Core Points and Arguments Mission and Focus - Lexeo Therapeutics aims to deliver therapies for challenging diseases, particularly focusing on cardiac health and genetic medicine [10][11] - The company is dedicated to reshaping heart health, with its first program targeting Friedreich's ataxia, a disease that significantly impacts cardiac function [10] Pipeline and Programs - **Friedreich's Ataxia Program**: - The company has received breakthrough designation for its Friedreich's ataxia program and initiated a natural history control study called CLARITY-FA [14] - The therapy, LX-2006, aims to deliver a functional copy of the Frataxin gene, which is crucial for cardiac health [20] - Clinical data shows a 33% reduction in left ventricular mass index (LVMI) at 12 months, indicating reversal of cardiac disease pathology [22] - The program is expected to move into pivotal trials (SUNRISE-FA2) in the first half of 2026 [17] - **Arrhythmogenic Cardiomyopathy Program (LX-2020)**: - The program targets a disease affecting approximately 60,000 patients in the U.S., with a mortality rate of 23% due to arrhythmias [24] - The therapy aims to restore the plakophilin-2 gene, which is essential for cell-cell junction function [25] - Early data shows a 22% reduction in nonsustained ventricular tachycardia (VT) at six months, with potential for deeper reductions over time [28][38] Financial Position - Lexeo has completed financings totaling approximately $230 million, securing a runway into 2028, which supports ongoing studies and operational needs [15][31] Safety and Efficacy - The AAVrh10 capsid used in therapies has shown a compelling safety profile, with no grade three serious adverse events (SAEs) reported [40][41] - The company emphasizes the importance of safety in gene therapy, particularly in the context of cardiac diseases [45] Strategic Direction - Lexeo is focusing on cardiovascular genetic medicine, having shifted away from its CNS pipeline to capitalize on opportunities in the cardiovascular space [32] - The company is exploring localized delivery methods in collaboration with Johnson & Johnson to address diseases requiring higher protein doses [18][33] Additional Important Content - The company is positioned as a leader in cardiac genetic medicines, addressing high unmet needs with no existing treatments [30] - Lexeo's innovative manufacturing platform allows for flexibility in supplying vectors for both small and large patient populations [14] - The company is optimistic about the potential for its therapies to change the standard of care for patients with Friedreich's ataxia and arrhythmogenic cardiomyopathy [23][24] Conclusion - Lexeo Therapeutics is advancing its pipeline with promising data in both Friedreich's ataxia and arrhythmogenic cardiomyopathy, supported by a strong financial position and a focus on safety and efficacy in gene therapy. The strategic shift towards cardiovascular genetic medicine positions the company well for future growth and impact in the biotech industry.

PresentationI would now like to turn the conference call over to Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics. Louis, please go ahead.Good morning, and welcome to Lexeo Therapeutics webcast presentation on LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy. As a reminder, this call is being recorded today, January 12.Louis TamayoCFO & Principal Accounting Officer Earlier today, we released interim data from the Lexeo HEROIC-PKP2 Phase I/II clinical trial of LX2020 for t ...

Lexeo Therapeutics Conference Call Summary Company Overview - **Company**: Lexeo Therapeutics (NasdaqGM:LXEO) - **Product**: LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (ACM) Key Industry Insights - **Disease Context**: PKP2-associated ACM affects approximately 60,000 people in the U.S. and is characterized by high risks of cardiac rhythm abnormalities, heart failure, and sudden cardiac death. Over 20% of patients experience sudden cardiac death as their first symptom [doc id='6'][doc id='14']. - **Current Treatment Limitations**: Existing treatments, including ICDs and medications like beta-blockers, do not address the underlying genetic cause of the disease [doc id='7'][doc id='14']. Core Findings from Clinical Trial - **Trial Design**: The Heroic PKP2 phase 1-2 clinical trial is an open-label, single-arm, multicenter trial assessing the safety and efficacy of LX2020 [doc id='15']. - **Participants**: 10 participants have been dosed, with 8 having at least six months of follow-up. The cohort includes patients with advanced disease progression, averaging nine years since diagnosis [doc id='16'][doc id='17']. - **Safety Profile**: LX2020 has been well tolerated with no serious adverse events reported. Some participants experienced elevated liver function tests, which were managed successfully [doc id='18'][doc id='19']. Efficacy Data - **PKP2 Protein Expression**: Significant increases in PKP2 protein expression were observed, with robust vector copy number and mRNA levels indicating effective transduction [doc id='20'][doc id='21']. - **Arrhythmia Burden Reduction**: - **Premature Ventricular Contractions (PVCs)**: A mean improvement of 14% was noted in the high-dose cohort, with stabilization or reduction in PVCs for the majority of participants [doc id='5'][doc id='23']. - **Non-Sustained Ventricular Tachycardia (NSVT)**: A mean improvement of 22% was observed in the high-dose cohort, with reductions in NSVT events indicating a potential decrease in the risk of sustained VT and ICD shocks [doc id='5'][doc id='23']. - **Clinical Measures**: Participants showed stabilization in cardiac function, with no changes in New York Heart Association Class reported [doc id='26']. Future Outlook - **Next Steps**: Enrollment for the Heroic study was completed in Q4 2025, with plans to provide twelve-month follow-up data for all high-dose participants by Q4 2026 [doc id='27']. - **Regulatory Engagement**: Discussions with the FDA regarding future trials and endpoints, particularly focusing on NSVT as a key measure, are anticipated [doc id='37']. Additional Considerations - **Patient Variability**: The trial includes patients with varying disease severity, which may influence the observed efficacy and safety outcomes [doc id='36']. - **Long-term Expectations**: There is optimism regarding the potential for further improvements in arrhythmia burden and cardiac function as data matures [doc id='47']. This summary encapsulates the key points from the Lexeo Therapeutics conference call, highlighting the company's focus on addressing a significant unmet medical need in the treatment of PKP2-associated arrhythmogenic cardiomyopathy through innovative gene therapy.

Core Insights - Lexeo Therapeutics announced preliminary data from the HEROIC-PKP2 Phase I/II clinical trial of LX2020, indicating that the treatment was generally well tolerated and led to significant improvements in PKP2 protein expression and arrhythmia burden in participants [2][3]. Group 1: Clinical Trial Results - The HEROIC-PKP2 trial involved ten participants, with three in the low-dose cohort and seven in the high-dose cohorts [4]. - LX2020 resulted in a mean increase in PKP2 protein expression of 93% in the low-dose cohort and 162% in the high-dose cohorts [8]. - Non-sustained ventricular tachycardia (NSVT) showed a 22% mean improvement in high-dose cohorts, while premature ventricular contractions (PVCs) had a 14% mean improvement [7][13]. - Four out of five participants in high-dose cohorts reported improvement on the Patient Global Impression of Change (PGIC) scale [13]. Group 2: Safety Profile - LX2020 was generally well tolerated, with no clinically significant complement activation reported [8]. - Elevations in liver function tests were observed in five participants at the high dose but resolved without complications [8]. - One serious adverse event of sustained ventricular tachycardia was noted, assessed as possibly treatment-related, but the participant was successfully treated [8]. Group 3: Next Steps and Future Outlook - The company plans to host a webcast to discuss these findings and future developments [9]. - Enrollment for the HEROIC-PKP2 trial was completed in Q4 2025, with 12-month data expected for all high-dose participants in Q4 2026 [13]. - Regulatory engagement is anticipated in 2026 as the company advances the development of LX2020 [13].

Core Insights - Lexeo Therapeutics has announced a research collaboration with Johnson & Johnson to explore localized cardiac delivery of gene therapy for cardiovascular diseases [1][2] - The collaboration aims to enhance the efficacy and safety of gene therapy by utilizing Impella heart pump technology for targeted delivery [1][2] Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company based in New York City, focused on innovative treatments for cardiovascular diseases [3] - The company is developing a portfolio of therapeutic candidates targeting genetic causes of conditions such as Friedreich ataxia cardiomyopathy and plakophilin-2 arrhythmogenic cardiomyopathy [3]

Core Viewpoint - Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is identified as a strong investment opportunity with significant upside potential, supported by positive analyst ratings and promising clinical trial results [1][2][4]. Group 1: Analyst Ratings and Price Targets - All eleven analysts covering Lexeo Therapeutics have a consensus buy rating, with a median price target of $19, indicating an upside potential of 79.92% from current levels [1]. - Raymond James initiated coverage with a 'Strong Buy' rating and a price target of $25, based on solid results from clinical trials and favorable FDA feedback [2]. - Cantor Fitzgerald reaffirmed an 'Overweight' rating with a price target of $19, also suggesting an upside potential of around 80% driven by the company's PKP2-ACM program [4]. Group 2: Clinical Trials and Revenue Projections - The lead candidate, LX2006, is an AAV gene therapy for cardiomyopathy associated with Friedreich's Ataxia, which is considered well-positioned for success in its pivotal trial [2]. - Raymond James anticipates LX2006 revenue of $14.1 million in FY27, potentially increasing to $805.3 million by FY32 [3]. Group 3: Company Overview - Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company based in New York, founded in 2017, with a pipeline that includes LX2006, LX2020, and LX2021 [5].